BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34901964)

  • 1.
    Altini C; Mammucci P; Pisani AR; D'Alò C; Sardaro A; Rubini D; Ferrari C; Rubini G
    Hell J Nucl Med; 2021; 24(3):239-246. PubMed ID: 34901964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
    Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
    Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Evaluation of Response Using
    Farag S; Geus-Oei LF; van der Graaf WT; van Coevorden F; Grunhagen D; Reyners AKL; Boonstra PA; Desar I; Gelderblom H; Steeghs N
    J Nucl Med; 2018 Feb; 59(2):194-196. PubMed ID: 28970330
    [No Abstract]   [Full Text] [Related]  

  • 4. 18F-Fluorodeoxyglucose positron emission tomography in evaluating treatment response to imatinib or other drugs in gastrointestinal stromal tumors: a systematic review.
    Treglia G; Mirk P; Stefanelli A; Rufini V; Giordano A; Bonomo L
    Clin Imaging; 2012; 36(3):167-75. PubMed ID: 22542374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of extension of gastrointestinal stromal tumors (GIST) treated with imatinib (Gleevec®) by 18F-FDG PET/CT.
    Valls-Ferrusola E; García-Garzón JR; Ponce-López A; Soler-Peter M; Fuertes-Cabero S; Moragas-Solanes M; Riera-Gil E; Carrió-Gasset I; Lomeña-Caballero F
    Rev Esp Enferm Dig; 2012 Jul; 104(7):360-6. PubMed ID: 22849497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07).
    Montemurro M; Cioffi A; Dômont J; Rutkowski P; Roth AD; von Moos R; Inauen R; Toulmonde M; Burkhard RO; Knuesli C; Bauer S; Cassier P; Schwarb H; Le Cesne A; Koeberle D; Bärtschi D; Dietrich D; Biaggi C; Prior J; Leyvraz S
    Cancer; 2018 Apr; 124(7):1449-1454. PubMed ID: 29315500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of (18) F-fluorodeoxyglucose positron emission tomography for prediction of treatment response in gastrointestinal stromal tumors: a systematic review and meta-analysis.
    Hassanzadeh-Rad A; Yousefifard M; Katal S; Asady H; Fard-Esfahani A; Moghadas Jafari A; Hosseini M
    J Gastroenterol Hepatol; 2016 May; 31(5):929-35. PubMed ID: 26642423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of F-18 FDG PET/CT for predicting malignant potential of gastrointestinal stromal tumors: A systematic review and meta-analysis.
    Kim SJ; Lee SW
    J Gastroenterol Hepatol; 2018 Mar; 33(3):576-582. PubMed ID: 28994187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed response on regorafenib treatment for GIST (gastro-intestinal stromal tumor) according to
    Van Weehaeghe D; Gheysens O; Vandecaveye V; Schöffski P; Van Laere K; Deroose CM
    BMC Cancer; 2018 Mar; 18(1):253. PubMed ID: 29506493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
    Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
    J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.
    Goldstein D; Tan BS; Rossleigh M; Haindl W; Walker B; Dixon J
    Oncology; 2005; 69(4):326-32. PubMed ID: 16293972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal Stromal Tumor of the Prostate: Staging and Evaluation of Response to Therapy With 18F-FDG PET/CT.
    Alabed YZ
    Clin Nucl Med; 2018 Jan; 43(1):52-54. PubMed ID: 29166334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
    Choi H; Charnsangavej C; Faria SC; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Benjamin RS
    J Clin Oncol; 2007 May; 25(13):1753-9. PubMed ID: 17470865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early response evaluation using 18F-FDG-PET/CT does not influence management of patients with metastatic gastrointestinal stromal tumors (GIST) treated with palliative intent.
    Farag S; IJzerman NS; Houdijk MPM; Reyners AKL; Arens AI; Grünhagen DJ; Desar IME; Gelderblom H; Steeghs N; de Geus-Oei LF
    Nuklearmedizin; 2021 Dec; 60(6):411-416. PubMed ID: 34479374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of early response to imatinib 800 mg after 400 mg progression by ¹⁸F-fluorodeoxyglucose PET in patients with metastatic gastrointestinal stromal tumors.
    Chacón M; Eleta M; Espindola AR; Roca E; Méndez G; Rojo S; Pupareli C
    Future Oncol; 2015; 11(6):953-64. PubMed ID: 25760976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.
    Van den Abbeele AD; Gatsonis C; de Vries DJ; Melenevsky Y; Szot-Barnes A; Yap JT; Godwin AK; Rink L; Huang M; Blevins M; Sicks J; Eisenberg B; Siegel BA
    J Nucl Med; 2012 Apr; 53(4):567-74. PubMed ID: 22381410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Early response to treatment with Glivec detected with 18F-FDG PET in a patient with gastrointestinal stromal tumor].
    Delgado Bolton RC; Ortega Candil A; Pérez Castejón MJ; Garcerant M; Cabrera Martín MN; Lapeña Gutiérrez L; Carreras Delgado JL
    Rev Esp Med Nucl; 2008; 27(2):112-7. PubMed ID: 18367049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multimodal functional imaging for early response assessment in patients with gastrointestinal stromal tumor treated with tyrosine kinase inhibitors.
    Revheim ME; Hole KH; Mo T; Bruland ØS; Reitan E; Julsrud L; Seierstad T
    Acta Radiol; 2022 Aug; 63(8):995-1004. PubMed ID: 34171968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET.
    Jager PL; Gietema JA; van der Graaf WT
    Nucl Med Commun; 2004 May; 25(5):433-8. PubMed ID: 15100500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography.
    Heinicke T; Wardelmann E; Sauerbruch T; Tschampa HJ; Glasmacher A; Palmedo H
    Anticancer Res; 2005; 25(6C):4591-4. PubMed ID: 16334147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.